CHITOSAN COATED SELENIUM-DONEPEZIL NANOPARTICLES AMELIORATE SCOPOLAMINE-INDUCED MEMORY IMPAIRMENT IN RATS
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53076Keywords:
Alzheimer's disease, Cognitive impairment, Memory enhancement, Nanoparticles, Oxidative stressAbstract
Objective: This study investigated the therapeutic potential of chitosan-coated Selenium-Donepezil Nanoparticles (SeNPs) in a scopolamine-induced rat model of Alzheimer's disease (AD).
Methods: Chitosan-coated SeNPs were synthesized and characterized using Field Emission Scanning Electron Microscopy (FE-SEM), Dynamic Light Scattering (DLS), Fourier-Transform Infrared Spectroscopy (FTIR), and Energy-Dispersive X-Ray Spectroscopy (EDAX). The therapeutic potential of SeNPs was evaluated in a scopolamine-induced rat model of AD by assessing spatial memory using the Morris Water Maze (MWM) test and passive avoidance test, as well as measuring oxidative stress markers, including the Ferric-Reducing Ability of Plasma (FRAP) and Malondialdehyde (MDA) levels.
Results: The selected formula (F2) of chitosan-coated SeNPs significantly improved spatial memory and reduced oxidative stress markers compared to scopolamine controls, suggesting a synergistic effect. The average size of F2 was approximately 200 nm, with a zeta potential of-20.4 mV. The loading efficiency of donepezil into F2 was 42.3±0.57%. In the MWM test, F2 significantly improved spatial memory and learning compared to the scopolamine group (p<0.01). F2 also ameliorated scopolamine-induced memory deficits in the passive avoidance test (p<0.05). Furthermore, F2 significantly increased FRAP levels and decreased MDA levels in both serum and brain tissue compared to the scopolamine group (p<0.05).
Conclusion: The results suggest that chitosan-coated SeNPs may offer a promising therapeutic approach for AD by targeting both oxidative stress and cholinergic dysfunction, warranting further investigation.
References
Johnson DK, Storandt M, Morris JC, Langford ZD, Galvin JE. Cog-nitive profiles in dementia: alzheimer disease vs healthy brain aging. Neurology. 2008;71(22):1783-9. doi: 10.1212/01.wnl.0000335972.35970.70, PMID 19029518.
Nasb M, Tao W, Chen N. Alzheimers disease puzzle: delving into pathogenesis hypotheses. Aging Dis. 2024;15(1):43-73. doi: 10.14336/AD.2023.0608, PMID 37450931.
Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Ta-mayol A. Alzheimers disease: treatment strategies and their limitations. Int J Mol Sci. 2022;23(22):13954. doi: 10.3390/ijms232213954, PMID 36430432.
Benilova I, DE Strooper B. Neuroscience promiscuous alzheimers amyloid: yet another partner. Science. 2013;341(6152):1354-5. doi: 10.1126/science.1244166, PMID 24052299.
Koc ER, Ilhan A, Ayturk Z, Acar B, Gurler M, Altuntas A. A comparison of hair and serum trace elements in patients with alzheimer disease and healthy participants. Turk J Med Sci. 2015;45(5):1034-9. doi: 10.3906/sag-1407-67, PMID 26738344.
Rayman MP. The importance of selenium to human health. Lan-cet. 2000;356(9225):233-41. doi: 10.1016/S0140-6736(00)02490-9, PMID 10963212.
Cardoso BR, Roberts BR, Bush AI, Hare DJ. Selenium selenopro-teins and neurod generative diseases. Metallomics. 2015;7(8):1213-28. doi: 10.1039/c5mt00075k, PMID 25996565.
Fibiger HC. Cholinergic mechanisms in learning memory and dementia: a review of recent evidence. Trends Neurosci. 1991;14(6):220-3. doi: 10.1016/0166-2236(91)90117-d, PMID 1716012.
Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR. Revisiting the cholinergic hypothesis in alzheimers disease: emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2019;6(1):2-15. doi: 10.14283/jpad.2018.43, PMID 30569080.
Blake MG, Krawczyk MDC, Baratti CM, Boccia MM. Neuropharmacology of memory consolidation and reconsolidation: insights on central cholinergic mechanisms. J Physiol Paris. 2014;108(4-6):286-91. doi: 10.1016/j.jphysparis.2014.04.005, PMID 24819880.
Maurer SV, Williams CL. The cholinergic system modulates memory and hippocampal plasticity via its interactions with non-neuronal cells. Front Immunol. 2017;8:1489. doi: 10.3389/fimmu.2017.01489, PMID 29167670.
Marucci G, Buccioni M, Dal Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in alzheimers disease. Neuropharmacology. 2021;190:108352. doi: 10.1016/j.neuropharm.2020.108352, PMID 33035532.
Jawaid T, Rai A, Kamal M. A comparative study of neuroprotec-tive effect of telmisartan and donepezil against lipopolysaccha-ride induced neuroinflammation in mice. Asian J Pharm Clin Res. 2015;8(6):68-72.
Ionescu Tucker A, Cotman CW. Emerging roles of oxidative stress in brain aging and alzheimers disease. Neurobiol Aging. 2021;107:86-95. doi: 10.1016/j.neurobiolaging.2021.07.014, PMID 34416493.
Nazıroglu M, Muhamad S, Pecze L. Nanoparticles as potential clinical therapeutic agents in alzheimers disease: focus on sele-nium nanoparticles. Expert Rev Clin Pharmacol. 2017;10(7):773-82. doi: 10.1080/17512433.2017.1324781, PMID 28463572.
Yamasaki M, Takeuchi T. Locus coeruleus and dopamine-dependent memory consolidation. Neural Plast. 2017;2017(1):8602690. doi: 10.1155/2017/8602690, PMID 29123927.
Rita Cardoso B, Silva Bandeira V, Jacob Filho W, Franciscato Cozzolino SM. Selenium status in elderly: relation to cognitive decline. J Trace Elem Med Biol. 2014;28(4):422-6. doi: 10.1016/j.jtemb.2014.08.009, PMID 25220532.
Mohammad Jafari R, Ala M, Goodarzi N, Dehpour AR. Does pharmacodynamics of drugs change after presenting them as nanoparticles like their pharmacokinetics? Curr Drug Targets. 2020;21(8):807-18. doi: 10.2174/1389450121666200128113547, PMID 32003669.
Skalickova S, Milosavljevic V, Cihalova K, Horky P, Richtera L, Adam V. Selenium nanoparticles as a nutritional supplement. Nutrition. 2017 Jan;33:83-90. doi: 10.1016/j.nut.2016.05.001, PMID 27356860.
Merten T, Henry M. Symptom and performance validity assess-ment in older adults and patients with dementia and claimed dementia. A handbook of geriatric neuropsychology. Routledge; 2022. p. 286-303.
Kaboli MA, Hashim AA, Altememy D, Saffari chaleshtori JS, Rezaee M, Hosseini SA. Silk fibroin-coated mesoporous silica nanoparticles enhance 6-thioguanine delivery and cytotoxicity in breast cancer cells. Int J App Pharm. 2025;17(1):275-83. doi: 10.22159/ijap.2025v17i1.52882.
Gao X, Lowry GV. Progress towards standardized and validated characterizations for measuring physicochemical properties of manufactured nanomaterials relevant to nano health and safety risks. Nano Impact. 2018;9:14-30. doi: 10.1016/j.impact.2017.09.002.
Cao Y, Zhang R. The application of nanotechnology in treatment of alzheimers disease. Front Bioeng Biotechnol. 2022;10:1042986. doi: 10.3389/fbioe.2022.1042986, PMID 36466349.
Singh B, Day CM, Abdella S, Garg S. Alzheimers disease current therapies novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402-24. doi: 10.1016/j.jconrel.2024.01.047, PMID 38286338.
Rahnama S, Rabiei Z, Alibabaei Z, Mokhtari S, Rafieian Kopaei M, Deris F. Anti-amnesic activity of Citrus aurantium flowers ex-tract against scopolamine-induced memory impairments in rats. Neurol Sci. 2015;36(4):553-60. doi: 10.1007/s10072-014-1991-2, PMID 25367404.
Cınar E, Mutluay SU, Baysal I, Gultekinoglu M, Ulubayram K, Ciftci SY. Donepezil-loaded PLGA-b-PEG nanoparticles enhance the learning and memory function of beta-amyloid rat model of alzheimers disease. Noro Psikiyatr Ars. 2022;59(4):281-9. doi: 10.29399/npa.28275, PMID 36514517.
Fathi F, Oryan S, Rafieian KopaeI M, Eidi A. Neuroprotective effect of pretreatment with Mentha longifolia L. extract on brain ischemia in the rat stroke model. Arch Biol Sci (Beogr). 2015;67(4):1151-63. doi: 10.2298/ABS150115091F.
George PM, Abernethy MH. Improved ellman procedure for erythrocyte cholinesterase. Clin Chem. 1983;29(2):365-8. doi: 10.1093/clinchem/29.2.365, PMID 6821947.
Morris R. Developments of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47-60. doi: 10.1016/0165-0270(84)90007-4, PMID 6471907.
Uddin MS, Kabir MT, Niaz K, Jeandet P, Clement C, Mathew B. Molecular insight into the therapeutic promise of flavonoids against alzheimers disease. Molecules. 2020;25(6):1267. doi: 10.3390/molecules25061267, PMID 32168835.
Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1(2):848-58. doi: 10.1038/nprot.2006.116, PMID 17406317.
Bajo R, Pusil S, Lopez ME, Canuet L, Pereda E, Osipova D. Sco-polamine effects on functional brain connectivity: a pharmacol-ogical model of alzheimers disease. Sci Rep. 2015;5(1):9748. doi: 10.1038/srep09748, PMID 26130273.
Jung HA, Jin SE, Choi RJ, Kim DH, Kim YS, Ryu JH. Anti-amnesic activity of neferine with antioxidant and anti-inflammatory ca-pacities as well as inhibition of ChEs and BACE1. Life Sci. 2010;87(13-14):420-30. doi: 10.1016/j.lfs.2010.08.005, PMID 20736023.
Xiao J, LI S, Sui Y, WU Q, LI X, Xie B. Lactobacillus casei-01 facili-tates the ameliorative effects of proanthocyanidins extracted from lotus seedpod on learning and memory impairment in scopolamine induced amnesia mice. PLOS One. 2014;9(11):e112773. doi: 10.1371/journal.pone.0112773, PMID 25396737.
Balaban H, Nazıroglu M, Demirci K, Ovey IS. The protective role of selenium on scopolamine-induced memory impairment oxi-dative stress and apoptosis in aged rats: the involvement of TRPM2 and TRPV1 channels. Mol Neurobiol. 2017;54(4):2852-68. doi: 10.1007/s12035-016-9835-0, PMID 27021021.
Samad N, Rao T, Rehman MH, Bhatti SA, Imran I. Inhibitory effects of selenium on arsenic-induced anxiety-/depression like behavior and memory impairment. Biol Trace Elem Res. 2022;200(2):689-98. doi: 10.1007/s12011-021-02679-1.
Godoi GL, DE Oliveira Porciuncula L, Schulz JF, Kaufmann FN, DA Rocha JB, DE Souza DO. Selenium compounds prevent amyloid β-peptide neurotoxicity in rat primary hippocampal neurons. Neurochem Res. 2013;38(11):2359-63. doi: 10.1007/s11064-013-1147-4, PMID 24013888.
Kaur K, Kaur R, Kaur M. Recent advances in alzheimers disease: causes and treatment. Int J Pharm Pharm Sci. 2016;8(2):8-15.
Ferro C, Florindo HF, Santos HA. Selenium nanoparticles for biomedical applications: from development and characteriza-tion to therapeutics. Adv Healthc Mater. 2021;10(16):e2100598. doi: 10.1002/adhm.202100598, PMID 34121366.
Pinton S, DA Rocha JT, Zeni G, Nogueira CW. Organoselenium improves memory decline in mice: involvement of acetylcholi-nesterase activity. Neurosci Lett. 2010;472(1):56-60. doi: 10.1016/j.neulet.2010.01.057, PMID 20122991.
JI D, WU X, LI D, Liu P, Zhang S, Gao D. Protective effects of chon-droitin sulphate nano selenium on a mouse model of alzheimers disease. Int J Biol Macromol. 2020;154:233-45. doi: 10.1016/j.ijbiomac.2020.03.079, PMID 32171837.
Bashir DW, Rashad MM, Ahmed YH, Drweesh EA, Elzahany EA, Abou El-Sherbini KS. The ameliorative effect of nanoselenium on histopathological and biochemical alterations induced by melamine toxicity on the brain of adult male albino rats. Neurotoxicology. 2021 Sep;86:37-51. doi: 10.1016/j.neuro.2021.06.006, PMID 34216684.
Zhang J, Zhou X, YU Q, Yang L, Sun D, Zhou Y. Epigallocatechin-3-gallate (EGCG)-stabilized selenium nanoparticles coated with Tet-1 peptide to reduce amyloid-β aggregation and cytotoxicity. ACS Appl Mater Interfaces. 2014;6(11):8475-87. doi: 10.1021/am501341u, PMID 24758520.
Yin T, Yang L, Liu Y, Zhou X, Sun J, Liu J. Sialic acid (SA) modified selenium nanoparticles coated with a high blood brain barrier permeability peptide-B6 peptide for potential use in alzheimers disease. Acta Biomater. 2015 Oct;25:172-83. doi: 10.1016/j.actbio.2015.06.035, PMID 26143603.
Wang Z, Wang Y, LI W, Mao F, Sun Y, Huang L. Design synthesis and evaluation of multitarget directed selenium-containing clioquinol derivatives for the treatment of alzheimers disease. ACS Chem Neurosci. 2014;5(10):952-62. doi: 10.1021/cn500119g, PMID 25121395.
Douchamps V, Mathis C. A second wind for the cholinergic sys-tem in alzheimers therapy. Behav Pharmacol. 2017;28(2-3):112-23. doi: 10.1097/FBP.0000000000000300, PMID 28240674.
Barbosa FA, Canto RF, Teixeira KF, DE Souza AS, DE Oliveira AS, Braga AL. Selenium derivative compounds: a review of new perspectives in the treatment of alzheimers disease. Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454, PMID 35209817.
Leuner K, Muller WE, Reichert AS. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of alzheimers disease. Mol Neurobiol. 2012;46(1):186-93. doi: 10.1007/s12035-012-8307-4, PMID 22833458.
Demirci K, Nazıroglu M, Ovey IS, Balaban H. Selenium attenuates apoptosis inflammation and oxidative stress in the blood and brain of aged rats with scopolamine-induced dementia. Metab Brain Dis. 2017;32(2):321-9. doi: 10.1007/s11011-016-9903-1, PMID 27631101.
Tonnies E, Trushina E. Oxidative stress synaptic dysfunction and alzheimers disease. J Alzheimers Dis. 2017;57(4):1105-21. doi: 10.3233/JAD-161088, PMID 28059794.
Published
How to Cite
Issue
Section
Copyright (c) 2025 FARIBA HOUSHMAND, ALAA A. HASHIM, HUSSEIN ABDELAMIR MOHAMMAD, FATEMEH DRISS, FATEMEH IRANPOUR, REZA AHMADI, NARGES NAJAFI, DHIYA ALTEMEMY, PEGAH KHOSRAVIAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
